PCM and TAT Co-modified Liposome with Improved Myocardium Delivery: in Vitro and in Vivo Evaluations

Overview

Journal Drug Deliv

Specialty Pharmacology

Date 2017 Feb 7

PMID 28165817

Citations 10

Authors

Xin Wang

Hua Huang

Liangke Zhang

Yan Bai

Huali Chen

Affiliations

Soon will be listed here.

Abstract

In this study, PCM and TAT co-modified liposome was developed as a novel drug carrier for myocardium delivery with evaluation of its in vitro and in vivo properties. Liposomes containing fluorescent probe coumarin-6 were prepared by thin-film hydration. The PCM ligands specifically bind to the PCM receptors in the extracellular connective tissue of primary myocardium cells (MCs), while the TAT ligands functioned as a classical cell penetrating peptide to make liposomes internalized by MCs. The unmodified liposome (L), PCM-modified liposome (PL), TAT-modified liposome (TL) and PCM and TAT co-modified liposome (PTL) were prepared and characterized. The cellular uptake and intracellular distribution of various liposomes by MCs demonstrated that PTL had the best delivery capability. Peptide inhibition assay indicated that the uptake of PL could be inhibited by PCM. However, TAT could almost not suppress the uptake of TL. In addition, the CCK-8 experiments showed that liposomes had low cytotoxicity. In vivo fluorescent images of frozen sections and HPLC-fluorescence analysis further demonstrated that PTL had highest myocardium distribution. The results of this study demonstrated that PCM and TAT co-modifying could improve the myocardial targeting ability of liposome.

Citing Articles

Illuminating the Molecular Intricacies of Exosomes and ncRNAs in Cardiovascular Diseases: Prospective Therapeutic and Biomarker Potential.

Khan F, Uddin S, Elderdery A, Goh K, Ming L, Ardianto C Cells. 2022; 11(22).

PMID: 36429092 PMC: 9688392. DOI: 10.3390/cells11223664.

Overcoming the cellular barriers and beyond: Recent progress on cell penetrating peptide modified nanomedicine in combating physiological and pathological barriers.

Liu Y, Zhao Z, Li M Asian J Pharm Sci. 2022; 17(4):523-543.

PMID: 36105313 PMC: 9458999. DOI: 10.1016/j.ajps.2022.05.002.

Nanoplateletsomes restrain metastatic tumor formation through decoy and active targeting in a preclinical mouse model.

Zhang L, Zhu Y, Wei X, Chen X, Li Y, Zhu Y Acta Pharm Sin B. 2022; 12(8):3427-3447.

PMID: 35967283 PMC: 9366539. DOI: 10.1016/j.apsb.2022.01.005.

Nanocarrier-Based Targeted Therapies for Myocardial Infarction.

George T, Hsu C, Meeson A, Lundy D Pharmaceutics. 2022; 14(5).

PMID: 35631516 PMC: 9143269. DOI: 10.3390/pharmaceutics14050930.

Engineering Cardiac Small Extracellular Vesicle-Derived Vehicles with Thin-Film Hydration for Customized microRNA Loading.

Bheri S, Kassouf B, Park H, Hoffman J, Davis M J Cardiovasc Dev Dis. 2021; 8(11).

PMID: 34821688 PMC: 8626043. DOI: 10.3390/jcdd8110135.

References

Scott R, Rosano J, Ivanov Z, Wang B, Chong P, Issekutz A . Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function. FASEB J. 2009; 23(10):3361-7. DOI: 10.1096/fj.08-127373. View

Ferrante E, Pickard J, Rychak J, Klibanov A, Ley K . Dual targeting improves microbubble contrast agent adhesion to VCAM-1 and P-selectin under flow. J Control Release. 2009; 140(2):100-7. PMC: 2783796. DOI: 10.1016/j.jconrel.2009.08.001. View

Li H, Yuan D, Sun M, Ping Q . Effect of ligand density and PEG modification on octreotide-targeted liposome via somatostatin receptor in vitro and in vivo. Drug Deliv. 2016; 23(9):3562-3572. DOI: 10.1080/10717544.2016.1209797. View

Fittipaldi A, Giacca M . Transcellular protein transduction using the Tat protein of HIV-1. Adv Drug Deliv Rev. 2005; 57(4):597-608. DOI: 10.1016/j.addr.2004.10.011. View

Joliot A, Prochiantz A . Transduction peptides: from technology to physiology. Nat Cell Biol. 2004; 6(3):189-96. DOI: 10.1038/ncb0304-189. View

Bazile D, Prudhomme C, Bassoullet M, Marlard M, Spenlehauer G, Veillard M . Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci. 1995; 84(4):493-8. DOI: 10.1002/jps.2600840420. View

Koren E, Apte A, Sawant R, Grunwald J, Torchilin V . Cell-penetrating TAT peptide in drug delivery systems: proteolytic stability requirements. Drug Deliv. 2011; 18(5):377-84. PMC: 3482480. DOI: 10.3109/10717544.2011.567310. View

Yuan M, Qiu Y, Zhang L, Gao H, He Q . Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma. Drug Deliv. 2015; 23(4):1171-83. DOI: 10.3109/10717544.2015.1040527. View

Ishida T, Iden D, Allen T . A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett. 1999; 460(1):129-33. DOI: 10.1016/s0014-5793(99)01320-4. View

10.

McGuire M, Samli K, Johnston S, Brown K . In vitro selection of a peptide with high selectivity for cardiomyocytes in vivo. J Mol Biol. 2004; 342(1):171-82. DOI: 10.1016/j.jmb.2004.06.029. View

11.

Noble G, Stefanick J, Ashley J, Kiziltepe T, Bilgicer B . Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol. 2013; 32(1):32-45. DOI: 10.1016/j.tibtech.2013.09.007. View

12.

Kluza E, Jacobs I, Hectors S, Mayo K, Griffioen A, Strijkers G . Dual-targeting of αvβ3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. J Control Release. 2011; 158(2):207-14. DOI: 10.1016/j.jconrel.2011.10.032. View

13.

Dasa S, Suzuki R, Gutknecht M, Brinton L, Tian Y, Michaelsson E . Development of target-specific liposomes for delivering small molecule drugs after reperfused myocardial infarction. J Control Release. 2015; 220(Pt A):556-567. PMC: 6113056. DOI: 10.1016/j.jconrel.2015.06.017. View

14.

Sutton M, Sharpe N . Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000; 101(25):2981-8. DOI: 10.1161/01.cir.101.25.2981. View

15.

Liu M, Li M, Sun S, Li B, Du D, Sun J . The use of antibody modified liposomes loaded with AMO-1 to deliver oligonucleotides to ischemic myocardium for arrhythmia therapy. Biomaterials. 2014; 35(11):3697-707. DOI: 10.1016/j.biomaterials.2013.12.099. View

16.

Won Y, Bull D, Kim S . Functional polymers of gene delivery for treatment of myocardial infarct. J Control Release. 2014; 195:110-9. PMC: 4252832. DOI: 10.1016/j.jconrel.2014.07.041. View

17.

Banks W, Robinson S, Nath A . Permeability of the blood-brain barrier to HIV-1 Tat. Exp Neurol. 2005; 193(1):218-27. DOI: 10.1016/j.expneurol.2004.11.019. View

18.

Ko Y, Hartner W, Kale A, Torchilin V . Gene delivery into ischemic myocardium by double-targeted lipoplexes with anti-myosin antibody and TAT peptide. Gene Ther. 2008; 16(1):52-9. DOI: 10.1038/gt.2008.135. View

19.

Katanasaka Y, Ida T, Asai T, Shimizu K, Koizumi F, Maeda N . Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416. Cancer Lett. 2008; 270(2):260-8. DOI: 10.1016/j.canlet.2008.05.009. View

20.

Liang W, Levchenko T, Khaw B, Torchilin V . ATP-containing immunoliposomes specific for cardiac myosin. Curr Drug Deliv. 2005; 1(1):1-7. DOI: 10.2174/1567201043480063. View